Antiparkinson Agents/therapeutic use; Dopaminergic Neurons/drug effects; Intracellular Signaling Peptides and Proteins/therapeutic use; Leupeptins/toxicity; Neuroprotective Agents/therapeutic use; Oncogene Proteins/therapeutic use; Oxidopamine/toxicity; Parkinsonian Disorders/prevention & control; Animals; Antiparkinson Agents/administration & dosage; Apomorphine/antagonists & inhibitors; Corpus Striatum/drug effects; Corpus Striatum/metabolism; Corpus Striatum/pathology; Dopamine/analysis; Dopaminergic Neurons/enzymology; Drug Evaluation, Preclinical; Humans; Hypoxia-Inducible Factor 1, alpha Subunit/biosynthesis; Hypoxia-Inducible Factor 1, alpha Subunit/genetics; Intracellular Signaling Peptides and Proteins/administration & dosage; Ion Channels/biosynthesis; Ion Channels/genetics; Male; Microinjections; Mitochondrial Membrane Transport Proteins/biosynthesis; Mitochondrial Membrane Transport Proteins/genetics; Mitochondrial Proteins/biosynthesis; Mitochondrial Proteins/genetics; Mitochondrial Uncoupling Proteins; Motor Activity/drug effects; Nerve Tissue Proteins/analysis; Nerve Tissue Proteins/biosynthesis; Nerve Tissue Proteins/genetics; Neuroprotective Agents/administration & dosage; Oncogene Proteins/administration & dosage; Oxidative Stress/drug effects; Parkinsonian Disorders/chemically induced; Parkinsonian Disorders/drug therapy; Protein Deglycase DJ-1; Rats; Rats, Sprague-Dawley; Substantia Nigra/drug effects; Substantia Nigra/metabolism; Substantia Nigra/pathology; Superoxide Dismutase/biosynthesis; Superoxide Dismutase/genetics; Tyrosine 3-Monooxygenase/analysis; alpha-Synuclein/biosynthesis; alpha-Synuclein/genetics